Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation

Article Abstract:

Breast cancer patients who have had a mastectomy or lumpectomy followed by radiotherapy applied to the entire breast may benefit from additional radiotherapy aimed at the area where the tumor was. In a study of 5,318 women, this additional radiotherapy decreased the risk of cancer recurrence, particularly in women 40 years old or younger.

Breast cancer

---

Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer

Article Abstract:

Daily treatment with cisplatin combined with radiotherapy may increase the chances of survival for patients with inoperable lung cancer that has not spread. A group of 331 patients with inoperable non-small-cell lung cancer were given either radiotherapy alone, radiotherapy with a weekly dose of cisplatin or radiotherapy with a daily dose of cisplatin. The percentage of patients surviving in the group given radiotherapy with daily cisplatin was 54% after one year, 26% after two years and 16% after three years. Survival rates in the group receiving radiotherapy with weekly cisplatin were 44% after one year, 19% after two years and 13% after three years. In the group receiving radiotherapy alone, survival rates were 46% after one year, 13% after two years and two percent after three years. Thirty-one percent of the patients in the daily-cisplatin group survived two years without a recurrence of cancer, compared to 30% of patients in the weekly-cisplatin group and 19% percent of patients in the radiotherapy-only group. Seventy-eight percent of the patients in the cisplatin-daily group and 86% of the patients in the cisplatin-weekly group experienced nausea and vomiting.

Health aspects, Lung cancer, Cisplatin

---

Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin

Article Abstract:

Giving patients with prostate cancer goserelin in addition to radiation therapy may improve survival rates. Goserelin is a chemical that mimics the action of gonadotropin-releasing hormone and thereby reduces testosterone levels. A total of 401 patients with prostate cancer were randomly assigned to receive radiation treatment alone or radiation plus goserelin, which was administered as monthly injections. At five years, overall survival rates were 79% in the men who received combination therapy and 62% in those who received radiation alone. Disease-free 5-year survival rates were 85% and 48%, respectively.

Prostate cancer, Goserelin

Similar abstracts:

• Abstracts: Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infections in adults
• Abstracts: Three births after preimplantation genetic diagnosis for cystic fibrosis with sequential first and second polar body analysis
• Abstracts: Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Profiling familial breast cancer
• Abstracts: Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1
• Abstracts: Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.